



The AIDS Clinical Trials Group (ACTG) Network is the largest HIV/AIDS clinical trials organization in the world. We currently have 34 domestic & 25 international sites.



## 2015 Annual ACTG Network Meeting Wrap-Up



(L to R) Dr. Daniel Kuritzkes, Dr. Anthony Fauci, Dr. Judith Currier, Dr. Ian Sanne

### 2015 Network Meeting Overview

The 2015 Annual ACTG Network Meeting took place June 22nd- June 26th in Washington DC, USA. With over 800 attendees, the meeting served as a platform to share recent ACTG Network trial updates as well as bring together community members and researchers to address future scientific agendas. In addition, the meeting offered three plenary talks and many other presentations all focused on our mission of reducing the burden of disease due

to HIV, tuberculosis and viral hepatitis.

### 2015 Network Meeting Plenary Talk

Dr. Anthony Fauci, Director of the National Institute for Allergy and Infectious Diseases (NIAID), gave the opening plenary talk and highlighted the need for continued funding for HIV research. In addition, he addressed the importance of gaining a better understanding of the HIV reservoir as we work to develop a safe, simple and scalable cure for HIV. To view Dr. Fauci's slide presentation, click [here](#).

### 2015 Network Meeting Highlighted Presentations

Among the many presentations at the meeting this year, several provided important updates and/or results for ongoing or recently completed ACTG Network trials. To review some of the highlighted presentations, click [here](#).

### **2015 Network Meeting Awards**

Each year, at the meeting, select researchers are given awards for their contribution to a specific field of ACTG Network research. These include: the John Carey Young Investigators Award, the Donna Davis Award, the Constance B. Wofsy Women's Health Investigator Award and the Minority HIV/AIDS Investigator Mentoring Program Award. To see the 2015 award winners, click [here](#).

---

## ACTG Network Trial Update

### **A5264: A Randomized Evaluation of ART Alone or with Delayed Chemotherapy versus ART with Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings**

*Second Version of Protocol Seeks to Increase Enrollment*

According to the International Agency for Research on Cancer, Kaposi's Sarcoma is currently the most common diagnosed cancer in HIV/AIDS-infected adults across the continent of Africa and is the third leading cause of death among people initiating antiretroviral therapy (ART) in Africa. Known as AIDS-KS, the condition results from co-infection with HIV/AIDS and Kaposi's Sarcoma Associated Herpes Virus. Although AIDS-KS has seen dramatic drops in rates in the United States, it remains an important cause of morbidity and mortality in Africa, particularly Sub-Saharan Africa (SSA) in countries including Uganda, Malawi, Kenya and Zimbabwe. With that in mind, protocol ACTG A5264 was launched in 2011 to compare ART with delayed chemotherapy versus ART with immediate chemotherapy for limited AIDS-KS in resource limited settings. [Read more>>](#)

---

## CAB Accepting Applications for Community Scientific Subcommittee Membership

### **Interested in Serving on the ACTG Community Scientific Subcommittee?**

The ACTG Community Scientific Subcommittee (CSS) is accepting applications for membership. The CSS seeks qualified individuals from U.S. and International ACTG sites to apply for membership. The composition of the CSS is mandated to reflect the impact of the domestic and international HIV epidemic and its co-infections, including tuberculosis and hepatitis, in the areas served by the ACTG network. HIV positive people, HIV community advocates, MSM, men and women of color, and young adults are encouraged to apply. Membership in ACTG Community Advisory Boards (CABs) is looked upon

favorably in the application process. All applicants must possess a fundamental knowledge of HIV disease and treatment issues. The business of the ACTG is conducted in English. Reliable access to the Internet and a computer are required. For additional information and to learn more about the CSS membership application process, click [here](#).

---

## ACTG Network Social Media

**Facebook:** The ACTG Network's Facebook page provides timely and applicable information with posts that focus on the latest HIV/AIDS research and clinical trials. Feel free to "Like" or share this information with friends, family and members of the research community.

To visit our Facebook page, click [here](#).

**Twitter:** The ACTG Network's Twitter handle is @ACTGNetwork. Be sure to "Follow" us and be active in the Twittersphere. You can always find the information we share by searching the hashtags #HIV #AIDS and #ClinicalTrials.

To visit our Twitter page, click [here](#).

**Youtube:** The ACTG Network's YouTube page offers informative and educational videos regarding HIV research, photo albums highlighting our sites, interviews with clinicians and study participants and much more. In the near future, we will be posting a series of new videos that can be shared with potential study participants to help them better understand the ACTG Network and the clinical trials that we conduct.

To visit our YouTube page, click [here](#).

Please take a moment to review our social media guidelines by clicking [here](#).

---

## This Month in HIV/AIDS History

**July 1981:** The New York Times reports on cases of Kaposi's Sarcoma affecting 41 gay men in New York and California.

**July 1983:** San Francisco General Hospital opens the first dedicated AIDS ward in the U.S. It is fully occupied within days.

**July 1990:** The U.S. Congress enacts the Americans with Disabilities Act (ADA). The Act prohibits discrimination against individuals with disabilities, including people living with HIV/AIDS.

**July 2010:** The Obama Administration releases the first comprehensive National HIV/AIDS Strategy for the United States.

Source: AIDS.gov



Thank you for taking the time to read the ACTG Network's Monthly Newsletter. If you would like to be a guest blogger, have your clinical trial site highlighted or would like to nominate a colleague for the Spotlight, please [click here](#). We welcome your feedback.

Sincerely,

***Patrick Bayhille***

***Senior Research Communications Specialist***

***AIDS Clinical Trials Group Network***

[VISIT OUR WEBSITE](#)



Like us on Facebook

Follow us on [twitter](#)

Copyright © 2015. All Rights Reserved.